Quantumzyme to rename itself Quantum Genesis AI Corp.

Rhea-AI Filing Summary

Quantumzyme Corp. reported that its board and a majority stockholder approved an amendment to change the company’s name to Quantum Genesis AI Corp. The name change is not yet effective because the amended Articles of Incorporation still must be filed with the Nevada Secretary of State after completion of the Schedule 14C information statement process and the required 20-day waiting period under federal securities laws.

The company has also submitted a company-related action notification to FINRA to reflect the new name and request a new stock symbol. The change will not affect shareholder rights, the company’s authorized capital, issued and outstanding shares, CUSIP number, or par value. A new ticker symbol will be assigned by FINRA once it finishes reviewing the corporate action.

8-K Event Classification

Item 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

1 item

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance

The company amended its charter documents, bylaws, or changed its fiscal year.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What corporate action did Quantumzyme Corp. (QTZM) disclose in this 8-K?

The company disclosed that its board and a majority stockholder approved an amendment to change the company’s name from Quantumzyme Corp. to Quantum Genesis AI Corp..

Is the Quantumzyme Corp. name change to Quantum Genesis AI Corp. already effective?

No. The name change will become effective only after the company completes its Schedule 14C information statement process, the 20-day waiting period expires, and the Certificate of Amendment is filed with the Nevada Secretary of State.

Will the Quantumzyme (QTZM) name change affect shareholder rights or share structure?

According to the disclosure, the name change will not affect shareholder rights and will not change the company’s authorized capital, issued and outstanding shares, CUSIP number, or par value.

What is FINRA’s role in Quantumzyme Corp.’s planned name change?

The company has filed an Issuer Company-Related Action Notification Form with FINRA to reflect the new name and to apply for a new stock symbol, which FINRA will assign after reviewing the corporate action.

How was the Quantum Genesis AI Corp. name change approved?

The name change was approved by the company’s Board of Directors on November 30, 2025, and by the holder of a majority of the voting power of the company’s outstanding capital stock through written consent on the same date.

Will Quantumzyme Corp.’s ticker symbol QTZM change after the name change?

Yes, a new ticker symbol will be assigned by FINRA once it completes its review of the company’s corporate action request related to the name change.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/07/2026 - 04:26 PM Learn about SEC filing dates

0001663038false--07-31false00016630382025-11-302025-11-30iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 7, 2026 (November 30, 2025)

QUANTUMZYME CORP.

(Exact name of registrant as specified in its charter)

Nevada		000-56725		N/A
(State or other jurisdiction		(Commission File Number)		(IRS Employer
of Incorporation)				Identification Number)

15656 Bernardo Center Drive Suite 801

San Diego, CA 92127

Tel.: 858-203-0312

 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

QUANTUMZYME CORP.

Form 8-K

Current Report

Item 5.03 – Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On November 30, 2025, the Board of Directors of Quantumzyme Corp. (the “Company”) approved an amendment to the Company’s Articles of Incorporation to change the Company’s name from Quantumzyme Corp. to Quantum Genesis AI Corp. (the “Name Change”). On November 30, 2025, the holder of a majority of the voting power of the Company’s outstanding capital stock approved the Name Change by written consent.

The Company has not yet filed the Certificate of Amendment with the Nevada Secretary of State. The Certificate of Amendment will be filed following the completion of the Company’s Schedule 14C information statement process and the expiration of the applicable 20-day waiting period required under federal securities laws, at which time the Name Change may become effective. The Company has filed an Issuer Company-Related Action Notification Form with FINRA to give reflect the Name Change and to apply for a new stock symbol. To this end, we will endeavor to update our shareholders, and the markets generally, upon approval and deemed effectiveness by FINRA.

The Name Change will not affect the rights of shareholders and will not result in any change to the Company’s authorized capital, issued and outstanding shares, CUSIP number, or par value. A change to the Company’s ticker symbol will be assigned by FINRA upon completion of its review of the Company’s corporate action request.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		QUANTUMZYME CORP.
Dated: January 7, 2026		/s/ Naveen Krishnarao Kulkarni
		By: Naveen Krishnarao Kulkarni
		Its: Chief Executive Officer

3